​

MoonLake Immunotherapeutics (MLTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

MoonLake Immunotherapeutics Revenue Highlights

00

Main Segment (Y)

License

MoonLake Immunotherapeutics Revenue by Period

MoonLake Immunotherapeutics Revenue by Year

DateRevenueChange
2024-12-31-100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31--

MoonLake Immunotherapeutics generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

MoonLake Immunotherapeutics Revenue by Quarter

DateRevenueChange
2025-03-31--100.00%
2024-12-31$101.85K100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$19.74K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31--

MoonLake Immunotherapeutics generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

MoonLake Immunotherapeutics Revenue Breakdown

MoonLake Immunotherapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22
License$299.60M$299.60M$299.60M

MoonLake Immunotherapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (100.00%).

Quarterly Revenue by Product

Product/ServiceMar 25Dec 24Sep 24Mar 24Dec 23Jun 23Mar 23Sep 22Jun 22
License$299.60M-$299.60M$299.60M-$299.60M$299.60M$302.10M$302.10M

MoonLake Immunotherapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: License (100.00%).

MoonLake Immunotherapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
TVTXTravere Therapeutics$233.18M$81.73M
DAWNDay One Biopharmaceuticals$131.16M$29.21M
ACLXArcellx$107.94M$15.27M
AMLXAmylyx Pharmaceuticals$87.37M$-665.00K
GPCRStructure Therapeutics--
ETNB89bio--
AKROAkero Therapeutics--
ELVNEnliven Therapeutics--
CMPXCompass Therapeutics--
VTYXVentyx Biosciences--
NUVLNuvalent--
MLTXMoonLake Immunotherapeutics--
AVTEAerovate Therapeutics--
ABOSAcumen Pharmaceuticals--
TERNTerns Pharmaceuticals--
PLRXPliant Therapeutics--

MLTX Revenue FAQ

What is MoonLake Immunotherapeutics’s yearly revenue?

MoonLake Immunotherapeutics's yearly revenue for 2024 was $0, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. MLTX's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is MoonLake Immunotherapeutics’s quarterly revenue?

MoonLake Immunotherapeutics's quarterly revenue for Q1 2025 was $0, a -100.00% decrease from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $101.85K, a 100.00% increase from the previous quarter (Q3 2024), and a 416.01% increase year-over-year (Q4 2023). MLTX's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023).

What is MoonLake Immunotherapeutics’s revenue growth rate?

MoonLake Immunotherapeutics's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are MoonLake Immunotherapeutics’s revenue streams?

MoonLake Immunotherapeutics's revenue streams in c 24 are License

What is MoonLake Immunotherapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of MoonLake Immunotherapeutics was License. This segment made a revenue of $299.6M, representing 100.00% of the company's total revenue.